Hence, Bcl-xL is a target for polyploidy resistance and the cells with overexpression of Bcl-xL are more sensitive to Bcl-xL inhibition, supporting that ABT-263 serves as a promising method of reversing polyploidy drug resistance seen in more malignant AML cells. This evidence concerns the gene BCL2L1 and acute myeloid leukemia.